Glycemic management of type 2 diabetes: How tight is right and how to get there

Archives of Internal Medicine

Volumn 168, Issue 19, 2008, Pages 2064-2066

  Nathan, David M ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLIN DERIVATIVE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLITAZONE DERIVATIVE; GLUCAGON LIKE PEPTIDE; GLYCOSIDASE INHIBITOR; HEMOGLOBIN A1C; INSULIN; MEGLITINIDE; METFORMIN; ROSIGLITAZONE; SULFONYLUREA; TOLBUTAMIDE;

CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DRUG CHOICE; DRUG INDUSTRY; EDITORIAL; EPIDEMIC; GLYCEMIC CONTROL; HUMAN; INTENSIVE CARE; KIDNEY DISEASE; NEUROPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RETINOPATHY;

CARDIOVASCULAR DISEASES; DIABETES COMPLICATIONS; HUMANS; HYPOGLYCEMIC AGENTS;

EID: 54949136912     PISSN: 00039926     EISSN: 15383679     Source Type: Journal    
DOI: 10.1001/archinte.168.19.2064     Document Type: Editorial

References (21)

1. Roglic G, Unwin N, Bennett PH, et al. The burden of mortality attributable to diabetes: realistic estimates for the year 2000. Diabetes Care. 2005;28(9):2130-2135.
2. Diabetes Control and Complications Trial Research Group. The effect of intensive diabetes treatment on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329(14): 977-986.
3. Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract. 1995;28(2):103-117.
4. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) [published correction appears in Lancet. 1999;354(9178):602]. Lancet. 1998;352(9131): 837-853.
5. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) [published correction appears in Lancet. 1998;352(9139):1558]. Lancet. 1998;352(9131):854-865.
6. Nathan DM, Cleary PA, Backlund JY, et al; Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in type 1 diabetes mellitus. N Engl J Med. 2005;353(25):2643-2653.
7. Nathan DM. Some answers, more controversy, from UKPDS: United Kingdom Prospective Diabetes Study. Lancet. 1998;352(9131):832-833.
8. Action to Control Cardiovascular Risk in Diabetes Study Group; Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358(24):2545-2559.
9. ADVANCE Collaborative Group; Patel A, MacMahon S, Chalmers J, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358(24):2560-2572.
10. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes [published correction appears in N Engl J Med. 2007;357(1):100]. N Engl J Med. 2007;356(24):2457-2471.
11. Lincoff AM, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA. 2007;298(10):1180-1188.
12. Eurich DT, McAlister FA, Blackburn DF, et al. Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic review. BMJ. 2007; 335(7618):497-506.
13. Psaty BM, Furberg CD. The record on rosiglitazone and the risk of myocardial infarction. N Engl J Med. 2007;357(1):67-69.
14. Solomon DH, Winkelmayer WC. Cardiovascular risk and the thiazolidinediones: déjà vu all over again? JAMA. 2007;298(10):1216-1218.
15. Nathan DM. Rosiglitazone and cardiotoxicity - weighing the evidence. N Engl J Med. 2007;357(1):64-66.
16. Meinert CL, Knatterud GL, Prout TE, Klimt CR. A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes, II: mortality results. Diabetes. 1970;19(suppl):789-830.
17. Selvin E, Bolen S, Yeh H-C, et al. Cardiovascular outcomes in trials of oral diabetes medications: a systematic review. Arch Intern Med. 2008;168(19):2070-2080.
18. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM Trial. JAMA. 2003;290(4): 486-494.
19. Nathan DM, Buse JB, Davidson MB, et al; Professional Practice Committee, American Diabetes Association. European Association for the Study of Diabetes. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy [published simultaneously in Diabetes Care. 2006;29(8):1963-1972]. Diabetologia. 2006;49(8):1711-1721.
20. Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: update regarding thiazolidinediones [published simultaneously in Diabetes Care. 2008;31(1):173-175]. Diabetologia. 2008;51(1):8-11.
21. Knowler WC, Barrett-Connor E, Fowler SE, et al; Diabetes Prevention Program Research Group. Reduction in incidence of type 2 diabetes with life-style intervention or metformin. N Engl J Med. 2002;346(6):393-403.